Home
Pipeline
Inhaled Murepavadin
Balixafortide
Lonodelestat (external)
Breakthrough Platforms
Partnering
About us
Investor Relations
Corporate Governance*
Reporting*
Corporate Presentation
Share Information
Media Releases
Ad-hoc Releases
Calendar
Contact
Careers
Contact
News on home
Spexis
>
News on home
Latest news
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
See all news
This site uses cookies:
Find out more.
Accept